The stock of Viking Therapeutics Inc. (NASDAQ:VKTX) decreased by -$0.63 on Friday to finish at $14.47, down -4.17 percent. The last five days have seen an average of 2,150,649 shares of common stock traded. 29 times new highs were reached in the current year, with a gain of $5.15. The average number of shares traded over the last 20 days was 1,825,417, while the average volume over the last 50 days totaled 2,604,007.
VKTX stock dropped -7.12% since last month. On 08/07/23, the company’s shares reached a one-month low of $12.62. The stock touched a high of $25.72 on 05/23/23, after rallying from a low of $2.53 in 52 weeks. The price of VKTX stock has risen by 53.94% or $5.15 this year, reaching a new high 29 times. Still, the stock price is down -43.74% from the 52-week high.
Insider Transactions
VKTX stock investors should be aware that Viking Therapeutics Inc. (VKTX) stock had its last reported insider trading activity 90 days ago on May 16. On May 16, Director Rowland Charles A Jr sold 40,000 shares at $25.00 each. This transaction resulted in the insider making $1,000,000. On May 16, MACARTNEY LAWSON sold 16,000 shares at a price of US$24.00. After the transaction, the insider now owns 47,965 shares. President & CEO Lian Brian had earlier sold 45,000 shares on May 01 for $22.45 a share. The transaction was completed for $1,010,250.
Financial Health
For the three months ended June 29, Viking Therapeutics Inc.’s quick ratio was 29.60, while its current ratio was 29.60, indicating its ability to pay off its debt.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. VKTX’s return on assets (ROA) during the last 12 months has been -33.40%. In the meantime, the return on equity (ROE) for the last 12 months was -36.30%.
Earnings Surprise
According to Viking Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $323.4 million in cash and short-term investments. It was predicted that Viking Therapeutics Inc.’s quarterly earnings would be -$0.19, but it ended up being -$0.19. At the end of Viking Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 14.58 million, while its total debt was $1.41 million. Equity owned by shareholders amounts to $100.03 million.
Technical Picture
Here’s a quick look at Viking Therapeutics Inc.’s (VKTX) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 50.03%, suggesting the stock is Neutral, with a 71.32% historical volatility rate.
The stochastic %K and %D were 77.47% and 73.67% respectively, while the average true range (ATR) was 0.89. Based on the 14-day stochastic reading of 67.25%, the RSI (14) reading is 45.32%. On the 9-day MACD Oscillator, the stock is at 0.78, and the 14-day reading is at 0.73.
Analyst Ratings
Analysts have assigned Viking Therapeutics Inc. (VKTX) an Buy rating. VKTX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 10 others recommend it as a buy.
What is VKTX’s price target for the next 12 months?
The current consensus forecast for the stock is between $28.00 and $40.00, with a median target price of $34.00. In analyzing these forecasts, the average price target given by analysts for Viking Therapeutics Inc. (VKTX) is $33.80.
